EGFR and non-small cell lung carcinoma: The majority of NSCLC patients harbouring EGFR Ex20ins are resistant to clinically approved first- and second-generation EGFR TKIs with low response rates of between 0 and 27% and a median progression-free survival (PFS) of <3 months [48,49,50,51].